Evidence map›Paper›PMID 34646423›Full record

ReviewOxidative medicine and cellular longevity2021

Combating Oxidative Stress and Inflammation in COVID-19 by Molecular Hydrogen Therapy: Mechanisms and Perspectives.

Duried Alwazeer, Franky Fuh-Ching Liu, Xiao Yu Wu, Tyler W LeBaron

Open access · hybridAbstract readReview
In one paragraph

Review in Oxidative medicine and cellular longevity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
21.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 124 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Research progress in clinical utilization of HFrontiers in pharmacology · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Molecular Hydrogen in the Treatment of Respiratory Diseases.International journal of molecular sciences · 2025
    Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. HAntimicrobial agents and chemotherapy · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. A Review Article on Exercise Intolerance in Long COVID: Unmasking the Causes and Optimizing Treatment Strategies.Medical science monitor : international medical journal of experimental and clinical research · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 4 countries.

Duried AlwazeerDepartment of Nutrition and Dietetics, Faculty of Health Sciences, Igdir University, 76000 Igdır, Turkey.ORCID https://orcid.org/0000-0002-2291-1628
Franky Fuh-Ching LiuAdvanced Pharmaceutics and Drug Delivery Laboratory, Leslie L. Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada M5S 3M2.ORCID https://orcid.org/0000-0003-4282-6196
Xiao Yu WuAdvanced Pharmaceutics and Drug Delivery Laboratory, Leslie L. Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada M5S 3M2.ORCID https://orcid.org/0000-0002-5333-8115
Tyler W LeBaronCenter of Experimental Medicine, Institute for Heart Research, Slovak Academy of Sciences, Bratislava, Slovakia.ORCID https://orcid.org/0000-0001-9164-6728
3M (United States) · USIğdır Üniversitesi · TRSouthern Utah University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is a widespread global pandemic with nearly 185 million confirmed cases and about four million deaths. It is caused by an infection with the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which primarily affects the alveolar type II pneumocytes. The infection induces pathological responses including increased inflammation, oxidative stress, and apoptosis. This situation results in impaired gas exchange, hypoxia, and other sequelae that lead to multisystem organ failure and death. As summarized in this article, many interventions and therapeutics have been proposed and investigated to combat the viral infection-induced inflammation and oxidative stress that contributes to the etiology and pathogenesis of COVID-19. However, these methods have not significantly improved treatment outcomes. This may partly be attributable to their inability at restoring redox and inflammatory homeostasis, for which molecular hydrogen (H

Indexed as

COVID-19COVID-19 Drug TreatmentHumansHydrogenInflammationKelch-Like ECH-Associated Protein 1NF-E2-Related Factor 2NF-kappa BOxidative StressSARS-CoV-2Signal TransductionHydrogenKEAP1 protein, humanKelch-Like ECH-Associated Protein 1NFE2L2 protein, humanNF-E2-Related Factor 2NF-kappa B

Identifiers

PMID34646423
PMCPMC8505069
OpenAlexW3203691717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.